Metabolic Syndrome Is Associated With High Grade Gleason Score When Prostate Cancer Is Diagnosed on Biopsy
Metabolic Syndrome Is Associated With High Grade Gleason Score When Prostate Cancer Is Diagnosed on Biopsy
复制标题
DOI：
10.1002/pros.21364
复制
发表时间：
2011-10-01
期刊：
影响因子：
2.8
通讯作者：
Tubaro, Andrea
中科院分区：
文献类型：
--
作者：
De Nunzio, Cosimo;Freedland, Stephen J.;Tubaro, Andrea
背景。评估代谢综合征 (MS) 与接受前列腺活检的患者前列腺癌诊断和分级之间的关联。方法。从 2009 年起，前瞻性招募了连续一系列接受 12 点前列腺活检且 PSA 值≥ 4 ng/ml 和/或直肠指检 (DRE) 阳性的患者。活检前测量体重指数（BMI）、腰围和血压。血液样本检测：PSA、空腹血糖、甘油三酯和胆固醇 HDL。 MS 的存在根据成人治疗小组 III 标准进行定义。结果。 195 名患者入组，中位年龄和 PSA 分别为 69 岁和 5.6 ng/ml。 BMI 中位数为 27.6 kg/m(2)，其中 64 名患者 (33%) 被归类为肥胖（BMI >= 30 kg/m(2)）。 86 名患者 (44%) 患有 MS。 83 名患者 (43%) 经活检发现癌症； 37 人 (45%) 患有 MS，46 人 (55%) 没有 MS (P = 0.48)。 PSA 与较高的癌症风险独立相关（OR 1.12/1 U PSA，P = 0.01）。在 83 名前列腺癌患者中，42 名 (51%) 的格里森评分为 6（12 名 (28.5%) 表现为 MS），41 名 (49%) 的格里森评分 >= 7（25 名 (61%) 表现为 MS）。 MS 的存在与前列腺癌风险增加无关（OR：0.97，P = 0.94），但与 Gleason >= 7 风险增加相关（OR：3.82；P = 0.013）。结论。在我们的单中心研究中，当活检诊断出前列腺癌时，多发性硬化症与高格里森评分的风险增加相关。然而，这些结果应该在更大规模的多中心研究中得到证实。前列腺 71：1492-1498，2011。(C) 2011 Wiley-Liss, Inc.
BACKGROUND. To evaluate the association between metabolic syndrome (MS) and prostate cancer diagnosis and grade in patients undergoing prostate biopsy.METHODS. From 2009 onwards, a consecutive series of patients undergoing 12-core prostate biopsy for PSA value >= 4 ng/ml and/or positive digital rectal examination (DRE) were prospectively enrolled. Body mass index (BMI), waist circumferences, and blood pressure were measured before the biopsy. Blood samples were tested for: PSA, fasting glucose, triglycerides, and cholesterol HDL. MS presence was defined according to Adult Treatment Panel III criteria.RESULTS. One hundred ninety five patients were enrolled with a median age and PSA of 69 years and 5.6 ng/ml respectively. Median BMI was 27.6 kg/m(2) with 64 patients (33%) being classified as obese (BMI >= 30 kg/m(2)). Eighty-six patients (44%) had MS. Eighty-three patients (43%) had cancer on biopsy; 37 (45%) with MS and 46 (55%) without (P = 0.48). PSA was independently associated with higher risk of cancer (OR 1.12/1 U PSA, P = 0.01). Out of 83 patients with prostate cancer, 42 (51%) had Gleason score 6 (12 (28.5%) presented a MS) and 41 (49%) a Gleason score >= 7 (25 (61%) presented a MS). The presence of MS was not associated with an increased risk prostate cancer (OR: 0.97, P = 0.94) but with an increased risk of Gleason >= 7 (OR: 3.82; P = 0.013).CONCLUSIONS. In our single center study, MS is associated with an increased risk of high grade Gleason score when prostate cancer is diagnosed on biopsy. However, these results should be confirmed in a larger multicenter study. Prostate 71: 1492-1498, 2011. (C) 2011 Wiley-Liss, Inc.